To further substantiate the impact of P53wt on HELLS expression in vivo we evaluated tumor samples derived from N-RAS and MYC-driven murine HCCs either developed in a Trp53−/− or a Trp53+/+ background by immunoblotting. This evidence concerns the gene NRAS and neoplasm.